Bank of America’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-49,802
| Closed | -$184K | – | 7545 |
|
|
2017
Q4 | $184K | Buy |
49,802
+10,688
| +27% | +$43.8K | ﹤0.01% | 5447 |
|
|
2017
Q3 | $160K | Buy |
39,114
+749
| +2% | +$2.87K | ﹤0.01% | 5487 |
|
|
2017
Q2 | $142K | Buy |
38,365
+837
| +2% | +$3.32K | ﹤0.01% | 5468 |
|
|
2017
Q1 | $155K | Buy |
37,528
+35,975
| +2,316% | +$151K | ﹤0.01% | 5428 |
|
|
2016
Q4 | $7K | Buy |
1,553
+1,345
| +647% | +$8.7K | ﹤0.01% | 6649 |
|
|
2016
Q3 | $2K | Sell |
208
-8,843
| -98% | -$62.7K | ﹤0.01% | 6878 |
|
|
2016
Q2 | $51K | Buy |
9,051
+8,676
| +2,314% | +$58.9K | ﹤0.01% | 5832 |
|
|
2016
Q1 | $3K | Sell |
375
-3,145
| -89% | -$24.2K | ﹤0.01% | 6738 |
|
|
2015
Q4 | $46K | Buy |
3,520
+1,288
| +58% | +$22.2K | ﹤0.01% | 6079 |
|
|
2015
Q3 | $37K | Sell |
2,232
-1,044
| -32% | -$21.4K | ﹤0.01% | 6085 |
|
|
2015
Q2 | $73K | Buy |
3,276
+3,048
| +1,337% | +$48.2K | ﹤0.01% | 5763 |
|
|
2015
Q1 | $2K | Sell |
228
-369
| -62% | -$3.62K | ﹤0.01% | 6729 |
|
|
2014
Q4 | $7K | Sell |
597
-295
| -33% | -$3.2K | ﹤0.01% | 7189 |
|
|
2014
Q3 | $10K | Buy |
892
+683
| +327% | +$10.4K | ﹤0.01% | 7342 |
|
|
2014
Q2 | $5K | Sell |
209
-148
| -41% | -$2.61K | ﹤0.01% | 7672 |
|
|
2014
Q1 | $6K | Sell |
357
-1,108
| -76% | -$18.2K | ﹤0.01% | 7336 |
|
|
2013
Q4 | $15K | Buy |
1,465
+581
| +66% | +$6.5K | ﹤0.01% | 7157 |
|
|
2013
Q3 | $11K | Sell |
884
-19,433
| -96% | -$205K | ﹤0.01% | 7152 |
|
|
2013
Q2 | $192K | Buy |
+20,317
| New | +$261K | ﹤0.01% | 5658 |
|
Bank of America's CASC Position: Q1 2018 in Review
Bank of America sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 49,802 shares — an estimated $184K sold.
Bank of America first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $192K in Q2 2013. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Bank of America reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Bank of America sold 49,802 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $184K.
- Bank of America first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Bank of America's Cascadian Therapeutics, Inc. position peaked at $192K in Q2 2013.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Bank of America's 13F filing for Q1 2018, filed 15 May 2018.